CJC-1295: The GHRH-Receptor Mechanism and Its Studied Outcomes

CJC-1295 mechanism of action

CJC-1295 mechanism of action is GHRH-receptor agonism on pituitary somatotrophs. The GHRH receptor is Gs-coupled; agonism activates adenylate cyclase, raises intracellular cAMP, and drives the cAMP/PKA cascade that produces GH synthesis and pulsatile release ^[4]. Bilezikjian and Vale characterized this pathway in purified rat somatotrophs in 1989, establishing the guanine-nucleotide-dependent activation kinetics (Ka ~10^-8 M) and the tight correlation between cAMP elevation and GH release ^[4].

What CJC-1295 adds to native GHRH biology is duration. The D-Ala-2 substitution blocks DPP-IV cleavage; Gln-8 reduces asparagine deamidation; Ala-15 enhances bioactivity; Leu-27 prevents methionine oxidation ^[6]. The optional DAC linker — a maleimidopropionyl-lysine group at the C-terminus — covalently binds free Cys34 of endogenous serum albumin within minutes of subcutaneous injection. Albumin's long circulating half-life (~19 days) then carries the peptide through plasma at a published mean of 5.8-8.1 days ^[1]. The no-DAC variant retains only the four substitutions; its half-life is approximately 30 minutes ^[6].

Downstream of the pituitary, the cascade is conventional. GH stimulates hepatic IGF-1 synthesis; serum IGF-1 is the standard biomarker for GH-axis activation in CJC-1295 trials ^[1][11]. Teichman 2006 reported preserved physiologic pulsatility under sustained CJC-1295 with DAC exposure — the molecule did not flatten the GH curve into a continuous infusion-like state, a concern that had been raised theoretically ^[1].

Outcomes reported in CJC-1295 studies

The Teichman 2006 trial enrolled healthy adults aged 21-61 and dosed them at 30, 60, 125, and 250 mcg/kg as single subcutaneous CJC-1295 with DAC injections, with a separate ascending-dose multi-week arm. Single-dose results: dose-dependent 2- to 10-fold mean GH elevations for six or more days; 1.5- to 3-fold mean IGF-1 elevations for nine to eleven days ^[1]. Multi-dose results: weekly or biweekly dosing sustained IGF-1 above baseline for up to 28 days across 28- and 49-day study windows ^[1]. Reported as safe and relatively well tolerated, particularly at 30-60 mcg/kg ^[1].

Alba and colleagues in 2006 tested CJC-1295 in GHRH-knockout mice — animals that fail to grow without exogenous GHRH stimulation. Once-daily 2-mcg subcutaneous injections starting at one week of age normalized body weight and length over five weeks. Every-48-hour and every-72-hour dosing produced partial recovery without full normalization. Total pituitary RNA and GH mRNA rose, consistent with somatotroph proliferation ^[3].

Ionescu and Frohman in 2009 reported serum protein-profile shifts in normal adults receiving subcutaneous CJC-1295, consistent with downstream GH/IGF-1 axis activation rather than direct pleiotropic effects of the peptide ^[5]. Sigalos 2017 documented elevated IGF-1 in hypogonadal men receiving GH-secretagogue protocols (GHRH analogs and ghrelin-receptor agonists) alongside testosterone therapy ^[11].

Modified GRF 1-29 (no-DAC CJC-1295)

Modified GRF 1-29 is the no-DAC variant. The name reflects the four amino-acid substitutions (D-Ala-2, Gln-8, Ala-15, Leu-27) modifying the native GHRH (1-29) backbone, without the DAC albumin-binding linker ^[6]. The Coy 1994 work established that the D-Ala-2 substitution alone increases half-life and decreases metabolic clearance of GHRH (1-29) in normal men ^[6]. Native GHRH (1-29) — sermorelin — has a plasma half-life of approximately 11-12 minutes ^[7]; modified GRF 1-29 extends to approximately 30 minutes ^[6].

The nomenclature crossover matters because researchers and analytical chemists frequently refer to the same molecule under different names. Henninge and colleagues in 2010 identified CJC-1295 in an unknown pharmaceutical preparation seized by Norwegian customs via LC-HRMS/MS, confirming the C-terminal amidated 29-amino-acid sequence consistent with both with-DAC and no-DAC CJC-1295 ^[8]. Modern anti-doping detection methods now distinguish the two forms ^[12][14].

CJC-1295 + ipamorelin: the studied combination

Ipamorelin and CJC-1295 act on different receptors in the same axis. CJC-1295 is a GHRH-receptor agonist on pituitary somatotrophs; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Raun and colleagues in 1998 characterized ipamorelin as the first selective GH secretagogue that releases GH without significantly elevating ACTH or cortisol — even at doses more than 200-fold above the ED50 for GH release ^[2]. The two pathways are parallel arms of the GH-release machinery, which is the mechanistic basis for combining them.

The combination has not been validated in a controlled randomized trial. Most reports describing CJC-1295 plus ipamorelin protocols are clinic case-series, observational accounts, or analytical-chemistry detection reports — not Phase 3 efficacy studies. Sigalos 2017 measured IGF-1 elevation in hypogonadal men receiving combined GH-secretagogue therapy alongside testosterone replacement, suggesting the protocol produces a measurable GH-axis signal in human subjects, but the study was not a placebo-controlled CJC-1295-plus-ipamorelin RCT ^[11].

CJC-1295 vs ipamorelin: class difference

CJC-1295 vs ipamorelin is a class-difference question, not a same-class comparison. CJC-1295 is a GHRH analog — a peptide-receptor agonist that mimics the hypothalamic input to the pituitary ^[1]. Ipamorelin is a pentapeptide GH secretagogue — it activates the ghrelin receptor (GHS-R1a) on the same somatotrophs ^[2]. Different receptor, different signaling, same downstream output. The selectivity profile is what made ipamorelin notable in 1998: GH release without the cortisol or prolactin elevations seen with earlier GH secretagogues ^[2].

CJC-1295 vs sermorelin

Sermorelin is GHRH (1-29) with no stabilizing modifications — the unmodified bioactive sequence. Plasma half-life is approximately 11-12 minutes after IV or subcutaneous administration; subcutaneous bioavailability is approximately 6% ^[7]. Despite the rapid peptide clearance, the GH pulse sermorelin triggers persists 2-4 hours, with peak GH at 30-60 minutes post-injection ^[7]. Sermorelin was approved by the FDA in 1997 (Geref, sermorelin acetate) for pediatric GH deficiency; the labeled product has since been discontinued in the US for commercial reasons unrelated to safety.

CJC-1295 was engineered to overcome sermorelin's pharmacokinetic limitation. The four substitutions extend the no-DAC half-life to ~30 minutes; the DAC linker extends the with-DAC half-life to ~8 days ^[1][6]. Same receptor, same downstream cascade. Different duration.

CJC-1295 vs recombinant HGH

Recombinant human growth hormone is GH itself, administered exogenously. CJC-1295 is upstream of GH — a GHRH-receptor agonist that stimulates the pituitary to release endogenous GH in pulses ^[1]. The downstream IGF-1 elevation is similar in kind but differs in pattern. Teichman 2006 reported preserved GH pulsatility under CJC-1295 with DAC, whereas exogenous recombinant GH bypasses the pituitary regulatory loop entirely ^[1]. Tesamorelin — a different GHRH analog, approved by the FDA in 2010 for HIV-associated lipodystrophy — produced a 15-18% mean reduction in visceral adipose tissue versus placebo in pivotal trials, establishing the clinical-grade evidence ceiling for GHRH-receptor agonism ^[9].

What is modified GRF 1-29?

An alternative name for CJC-1295 without DAC. The four amino-acid substitutions at positions 2, 8, 15, and 27 that stabilize the molecule against DPP-IV cleavage are the 'modifications' the name references ^[6]. Half-life is approximately 30 minutes — short compared with the ~8-day DAC variant, longer than native GHRH (1-29) at ~10 minutes ^[6][7].

How does CJC-1295 work?

Agonist at the pituitary GHRH receptor ^[4]. The DAC-bearing variant covalently binds serum albumin via the maleimide linker, producing a sustained plasma residence of approximately 5.8-8.1 days and a multi-day GH 'bleed' ^[1]. The no-DAC variant clears within ~30 minutes, producing a pulse closer to native GH physiology ^[6].

How does CJC-1295 differ from ipamorelin?

Different receptor targets. CJC-1295 is a GHRH-receptor agonist; ipamorelin is a selective ghrelin-receptor (GHSR-1a) agonist ^[2]. They act on different signaling pathways within the same GH-release axis, which is the mechanistic basis for combination protocols ^[11].

What does CJC-1295 + ipamorelin do?

Combination protocols pair GHRH-receptor agonism (CJC-1295) with ghrelin-receptor agonism (ipamorelin) to engage two parallel arms of GH-release physiology ^[1][2]. Most data is from clinic case series rather than controlled trials; Sigalos 2017 documented a measurable GH-axis signal in human subjects receiving combined GH-secretagogue therapy ^[11].

How does CJC-1295 compare to sermorelin?

Both are GHRH analogs. Sermorelin is GHRH (1-29) with no stabilizing modifications and an 11-12 minute half-life ^[7]. CJC-1295 carries four substitutions that extend half-life — to approximately 30 minutes for the no-DAC variant, and to a published mean of 5.8-8.1 days for the with-DAC variant via covalent albumin binding ^[1][6].

What is the difference between CJC-1295 and HGH?

Recombinant HGH is the growth hormone itself, administered exogenously. CJC-1295 is a GHRH-receptor agonist — it stimulates the pituitary to release the body's own GH in a more physiologically patterned way ^[1]. Different point of action on the GH/IGF-1 axis; different downstream pulsatility profile.